Fang Y - Search Results

1

Boosting CAR-T cell therapy through vaccine synergy.

Li YR, Lyu Z, Shen X, Fang Y, Yang L. Li YR, et al. Among authors: fang y. Trends Pharmacol Sci. 2025 Jan 3:S0165-6147(24)00270-0. doi: 10.1016/j.tips.2024.12.004. Online ahead of print. Trends Pharmacol Sci. 2025. PMID: 39755457 Free article. Review.

2

Frontiers in CAR-T cell therapy for autoimmune diseases.

Li YR, Lyu Z, Chen Y, Fang Y, Yang L. Li YR, et al. Among authors: fang y. Trends Pharmacol Sci. 2024 Sep;45(9):839-857. doi: 10.1016/j.tips.2024.07.005. Epub 2024 Aug 14. Trends Pharmacol Sci. 2024. PMID: 39147651 Free article. Review.

3

Managing allorejection in off-the-shelf CAR-engineered cell therapies.

Li YR, Fang Y, Niu S, Chen Y, Lyu Z, Yang L. Li YR, et al. Among authors: fang y. Mol Ther. 2024 Nov 26:S1525-0016(24)00762-7. doi: 10.1016/j.ymthe.2024.11.035. Online ahead of print. Mol Ther. 2024. PMID: 39600090 Free article. Review.

4

Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity.

Li YR, Brown J, Yu Y, Lee D, Zhou K, Dunn ZS, Hon R, Wilson M, Kramer A, Zhu Y, Fang Y, Yang L. Li YR, et al. Among authors: fang y. Cancers (Basel). 2022 Jun 1;14(11):2749. doi: 10.3390/cancers14112749. Cancers (Basel). 2022. PMID: 35681730 Free PMC article.

5

Tumor-Localized Administration of α-GalCer to Recruit Invariant Natural Killer T Cells and Enhance Their Antitumor Activity against Solid Tumors.

Li YR, Zhou Y, Wilson M, Kramer A, Hon R, Zhu Y, Fang Y, Yang L. Li YR, et al. Among authors: fang y. Int J Mol Sci. 2022 Jul 7;23(14):7547. doi: 10.3390/ijms23147547. Int J Mol Sci. 2022. PMID: 35886891 Free PMC article.

6

Graft-versus-Host Disease Modulation by Innate T Cells.

Fang Y, Zhu Y, Kramer A, Chen Y, Li YR, Yang L. Fang Y, et al. Int J Mol Sci. 2023 Feb 17;24(4):4084. doi: 10.3390/ijms24044084. Int J Mol Sci. 2023. PMID: 36835495 Free PMC article. Review.

7

Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy.

Chen Y, Zhu Y, Kramer A, Fang Y, Wilson M, Li YR, Yang L. Chen Y, et al. Among authors: fang y. Front Med (Lausanne). 2023 Mar 29;10:1135468. doi: 10.3389/fmed.2023.1135468. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37064017 Free PMC article. Review.

8

Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies.

Li YR, Fang Y, Lyu Z, Zhu Y, Yang L. Li YR, et al. Among authors: fang y. J Transl Med. 2023 Oct 2;21(1):686. doi: 10.1186/s12967-023-04575-9. J Transl Med. 2023. PMID: 37784157 Free PMC article. Review.

9

Advancements in CRISPR screens for the development of cancer immunotherapy strategies.

Li YR, Lyu Z, Tian Y, Fang Y, Zhu Y, Chen Y, Yang L. Li YR, et al. Among authors: fang y. Mol Ther Oncolytics. 2023 Oct 5;31:100733. doi: 10.1016/j.omto.2023.100733. eCollection 2023 Dec 19. Mol Ther Oncolytics. 2023. PMID: 37876793 Free PMC article. Review.

10

Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy.

Li YR, Zhou Y, Yu J, Zhu Y, Lee D, Zhu E, Li Z, Kim YJ, Zhou K, Fang Y, Lyu Z, Chen Y, Tian Y, Huang J, Cen X, Husman T, Cho JM, Hsiai T, Zhou JJ, Wang P, Puliafito BR, Larson SM, Yang L. Li YR, et al. Among authors: fang y. Mol Ther. 2024 Jun 5;32(6):1849-1874. doi: 10.1016/j.ymthe.2024.04.005. Epub 2024 Apr 6. Mol Ther. 2024. PMID: 38584391 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16,454 results

Search Page

Filters